HCW Biologics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
68.0%projected annual EPS growth
Analyst Coverage
1analyst covering
FY EPS (est.)
-$2.88next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
| Establishment of HCW9302 Recommended Phase 2 Dose | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Severity of Alopecia Tool (SALT) Score Reduction Quarterly25.0Target: >=25% reduction in SALT score across expanded cohorts
Quarterly Licensing Revenue Quarterly6.5MTarget: Establish recurring non-dilutive licensing streams
Cash and Cash Equivalents Quarterly1.2MTarget: Secure additional financing to alleviate going concern doubt
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: Maintaining a minimum bid price of $1.00 per shareAction: Monitor stock price and evaluate potential corporate actions if bid price remains below $1.00
- HCW9302 Recommended Phase 2 Dose (RP2D) SelectionTrigger: Completion of the 8 mcg/kg dose-escalation cohortAction: Establish the RP2D by year-end 2026 to initiate Phase 2 trials
- HCW11-040 IND-Enabling StudiesTrigger: Completion of IND-enabling studies in the second half of 2027Action: File IND application immediately after completion to evaluate in bronchopulmonary dysplasia (BPD)
Research as of 20 Jun 2026